D. Tseneklidou‐Stoeter

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)

Renchi Yang, L. Rusen, H. Beckmann et al. · Journal of Thrombosis and Haemostasis · 2014 · 88 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Efficacy and safety of BAY 81‐8973, a full‐length recombinant factor VIII: results from the LEOPOLD I trial

Kapil Saxena, Shadan Lalezari, Johannes Oldenburg et al. · Haemophilia · 2016 · 55 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

<scp>BAY</scp> 81‐8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the <scp>LEOPOLD</scp> Kids Trial

Rolf Ljung, Gili Kenet, Maria Elisa Mancuso et al. · Haemophilia · 2015 · 34 citations

Medicine, Hematology, Pediatrics +14

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to &gt;5 years with extended dosing intervals: PROTECT VIII extension interim results

Shadan Lalezari, Mark T. Reding, Ingrid Pabinger et al. · Haemophilia · 2019 · 27 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Safety and efficacy of <scp>BAY</scp> 81‐8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme

Johannes Oldenburg, Jerzy Windyga, K. K. Hampton et al. · Haemophilia · 2016 · 20 citations · Full text

Medicine, Hematology, Surgery +16